Related Experiment Video
Updated: Sep 4, 2025

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Current Status of ABO-incompatible Liver Transplantation.
Hiroto Egawa1, Hideki Ohdan2, Kazuhide Saito3
1Department of Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Strategies for preventing antibody-mediated rejection after ABO-incompatible liver transplants are established using rituximab and other agents. Further research is needed to personalize immunosuppression and prevent complications like infection.
Area of Science:
- Hepatology
- Immunology
- Transplantation Medicine
Background:
- Living donor liver transplantation (LDLT) is prevalent in Asia due to donor scarcity.
- ABO-incompatible (ABO-I) LDLT requires specific protocols to prevent antibody-mediated rejection (AMR).
- Established desensitization protocols have improved safety and efficacy in ABO-I LDLT.
Purpose of the Study:
- To review current strategies for preventing AMR in ABO-I LDLT.
- To discuss the role of rituximab and immunosuppression in ABO-I LDLT.
- To identify future directions for optimizing patient outcomes and minimizing complications.
Main Methods:
- Review of established desensitization protocols for ABO-I LDLT.
- Analysis of rituximab's safety and efficacy, including its impact on cancer recurrence.
- Exploration of genetic factors (SNPs) for personalized immunosuppression.
Main Results:
- A desensitization protocol with rituximab, plasma pheresis, tacrolimus, and mycophenolate mofetil is the current standard for ABO-I LDLT.
- Rituximab does not increase hepatocellular carcinoma recurrence risk.
- Genetic variations may guide immunosuppression adjustments to reduce infection risk.
Conclusions:
- Current protocols provide a safe and effective approach to ABO-I LDLT.
- Personalized immunosuppression strategies are needed to balance AMR prevention and infection risk.
- Further research into immunological accommodation mechanisms is warranted.
More Related Videos
11:25Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies
Published on: March 8, 2024
09:29Technique of Subnormothermic Ex Vivo Liver Perfusion for the Storage, Assessment, and Repair of Marginal Liver Grafts
Published on: August 13, 2014
Related Concept Videos
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
The ABO Blood Group
Antigens in the ABO Blood Group System
Antigens are substances that can trigger an immune response, leading to the production of antibodies. In the ABO blood group system,...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Kidney Transplant I: Introduction